Semi-immune individuals, such as the patient described by Allan and Tahir (April 2006 JRSM 1 ), present a diagnostic challenge in UK emergency departments due to the relatively uncommon presentation of malaria in these settings. The patient probably had recrudescent Plasmodium falciparum infection, caused by persistence of blood forms of P. falciparum in small numbers between attacks. Though exposed to infection in her country, the authors did not state if she had clinical infection prior to leaving, if it was treated, or if she took prophylactic medication before or after arriving in the UK.
Widespread anti-malarial drug resistance in Africa makes the possibility of recrudescent infection more significant.
The Health Protection Agency guidelines would thus provide the greatest sensitivity and specificity for diagnosing malaria. 1 Thrombocytopenia which is a relatively common presentation of malaria in Nigerians and other Africans in western countries, 2,3 may be a vital clue to the diagnosis in busy emergency departments.
Competing interests ATA is a Nigerian, and a senior house officer in Accident & Emergency medicine on the GPVTS of the Kent, Sussex, and Surrey postgraduate deanery. The proposition that chronic subdural haematoma (CSH) is largely amenable to surgical treatment 1 can only be substantiated, in the short term, by a national audit of neurosurgical practice, and, in the long term, by a randomized controlled trial. The latter strategy was the one suggested by a leading neurosurgical authority who noted that there were no randomized controlled trials to yield class I evidence supporting any of the treatment options for chronic subdural haematoma; and that the available class II evidence relied on only six trials. 2 What is even more worrying is the reliance, at least in one instance, on case control studies such as the one dating back to 1992, 3 which was subsequently cited as recently as 1999 to support a proposed management option for CSH. 4 In essence, that option was based on the premise that '. . . there is little point in active treatment over the age of 65 for those who remain in coma (Glasgow Come Scale 8 or less) for more than 6 hours . . .'. 4 Such statements, I maintain, should, at least, be qualified by the acknowledgement that, given the biological diversity of the over 65s, clinical outcomes in that age group might be better predicted by the biological age/physiological reserve index than by chronological age. 5
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